Patent application number | Description | Published |
20080206136 | Binding Peptidomimetics and Uses of the Same - A multimeric peptidomimetic that comprises two or more monomers is disclosed. The monomers comprise an exocyclic peptide comprising a ring structure, a flexible linker sequence and a multimeric motif. Use of the monomers, a nucleic acid molecule encoding monomers, recombinant expression vectors comprising the nucleic acid molecule and host cells comprising a recombinant expression vector are disclosed. Methods of delivering a drug, a toxin, a nucleic acid molecule, a radionuclide or a detectable compound to a cell are disclosed. | 08-28-2008 |
20090010935 | Compositions and Methods of Treating Tumors - Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed. | 01-08-2009 |
20090104191 | Prevention of tumors with monoclonal antibodies against neu - Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed. | 04-23-2009 |
20090221527 | TUMOR NECROSIS FACTOR INHIBITORS - The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions. | 09-03-2009 |
20090286737 | ERBB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF - Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed. | 11-19-2009 |
20090306030 | Methods Of Inhibiting Osteoclast Activity - Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems. | 12-10-2009 |
20100040618 | Prevention of tumors with monoclonal antibodies against neu - Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed. | 02-18-2010 |
20100076174 | ErbB Interface Peptidomimetics And Methods Of Use Thereof - Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed. | 03-25-2010 |
20100120688 | ErbB Interface Peptidomimetics And Methods Of Use Thereof - Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed. | 05-13-2010 |
20100151507 | Cavity Induced Allosteric Modification Of Intermolecular Interactions And Methods Of Identifying Compounds That Effect The Same - Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed. | 06-17-2010 |
20100189649 | MONOCLONAL ANTIBODIES TO ACTIVATED ERBB FAMILY MEMBERS AND METHODS OF USE - Antibodies which bind to activated members of the erbB, TNF, and IgSF family of receptors and pharmaceutical compositions comprising the same are disclosed. Peptides and mimetics of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are also described. Methods of using such antibodies, peptides, and mimetics in tumor therapeutic, prophylactic, imaging and diagnostic applications are disclosed. | 07-29-2010 |
20100239587 | ErbB Interface Peptidomimetics And Methods Of Use Thereof - Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed. | 09-23-2010 |
20100311669 | COMPOUNDS THAT BIND TO P185 AND METHODS OF USING THE SAME - Novel peptides and pharmaceutical compositions comprising the same are disclosed. Conjugated compositions peptides linked to detectable agents and/or cytotoxic agents. are disclosed. Method of detecting tumors that have p185 on tumor cell surfaces are disclosed. Methods of preventing transformation of a normal cell into a tumor cell in an individual at risk of developing a tumor having tumor cells which have p185 on their surfaces are disclosed. Methods of treating an individual who has cancer characterized by tumor cells that have a p185 on their cell surfaces are disclosed. | 12-09-2010 |
20110020332 | Prevention of tumors with monoclonal antibodies against neu - Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed. | 01-27-2011 |
20110124560 | FOXP3 OLIGOMERIZATION AND INTERMOLECULAR INTERACTIONS - Methods of identifying immune response modulators are disclosed. Some methods comprise identifying chemical candidates that modulate oligomerization of FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate the hetero-oligomerization of FOXP1 with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Some methods comprise identifying chemical candidates that modulate interaction of IL-2 promoter with FOXP3 and/or fragments thereof comprising the Zinc-LeuZip domains. Method of treating individuals who have or are suspected of having autoimmune disease, inflammatory disease, cell, tissue or organ transplantation, or coronary artery disease, and methods of treating individuals who have or are suspected of having infectious disease, cancer, or who are immunocompromised or undergoing vaccination are disclosed. | 05-26-2011 |
20110274688 | PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST NEU - Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface are disclosed. The methods comprise administering an antibody which specifically binds to p185. Methods of preventing the transformation of a normal cell into a tumor cell that has p185 on its surface in an individual at high risk of developing tumors are disclosed. | 11-10-2011 |
20110312920 | CAVITY INDUCED ALLOSTERIC MODIFICATION OF INTERMOLECULAR INTERACTIONS AND METHODS OF IDENTIFYING COMPOUNDS THAT EFFECT THE SAME - Method of identifying compounds that modulate intermolecular interactions between a target protein and a modifier are disclosed. Pharmaceutical composition comprising compounds that inhibit intermolecular interactions between a target protein and a modifier are disclosed. Methods of treating individual suffering from inflammatory conditions, undesirable immune responses, immunological conditions and bacterial infections are disclosed. | 12-22-2011 |
20120014965 | COMPOSITIONS AND METHODS OF TREATING TUMORS - Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed. | 01-19-2012 |
20120108559 | RECEPTOR ACTIVATOR OF THE RANK RECEPTOR COMPLEX INHIBITOR - Methods and pharmaceutical compositions utilizing compounds of Formula II: for inhibiting osteoclastogenesis and the activity of osteoclasts in patients. | 05-03-2012 |
20120122910 | METHOD OF TREATING CANCER USING A SURVIVIN INHIBITOR - Disclosed herein are methods of treating cancer by administering to a patient a small molecule inhibitor of Survivin. Also disclosed herein are methods of inhibiting Survivin dimerization in a patient by administering a compound of formula (I), (II), (III), or (IV). Methods of inducing cell cycle arrest in cancer cells, comprising G2/M stage arrest, in a patient by administering a compound of formula (I), (II), (III), or (IV) are also disclosed. Further disclosed herein are methods of inducing apoptosis in cancer cells in a patient by administering a compound of formula (I), (II), (III), or (IV). | 05-17-2012 |
20120164066 | ANTIGEN-BINDING PROTEINS COMPRISING RECOMBINANT PROTEIN SCAFFOLDS - Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use. | 06-28-2012 |
20120202848 | THERAPY OF AUTOIMMUNE COLITIS USING A TIP60 INHIBITOR - This invention is in the fields of immunology and autoimmunity. More particularly it concerns methods of treating patients with compounds which are useful agents for inhibiting the functions of TIP60 in the treatment of an individual suffering, for example, from ulcerative colitis and other irritable bowel diseases. | 08-09-2012 |
20120245081 | FAS PEPTIDE MIMETICS AND USES THEREOF - Exocyclic peptide mimetics that disable Fas were developed. A three dimensional model of the Fas receptor-ligand complex was constructed and structurally predicted regions of the receptor that were relevant to binding ligand were used to create constrained peptide mimetics. Exocyclic anti-Fas peptide mimetics were identified that block Fas receptor-ligand interactions, and modulate Fas biological activity both in vitro and in vivo. The mimetics are useful, e.g., for treating Fas-related pathologies. | 09-27-2012 |
20130072562 | TUMOR NECROSIS FACTOR INHIBITORS - The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions. | 03-21-2013 |
20130137774 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX - This application describes pharmaceutical compositions, commercial packages, and methods for inhibiting cell proliferative disorders, especially those disorders, including Her2 related cancers, characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, and methods for imaging an HER-2 expressing tumor. | 05-30-2013 |
20130190405 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX - This application describes pharmaceutical compositions, kits, and methods for inhibiting cell proliferative disorders, especially those disorders characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, including Her2 related cancers, and methods for imaging an Her-2 expressing tumor. | 07-25-2013 |
20130204069 | Compositions and Methods of Treating Tumors - Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed. | 08-08-2013 |
20130217857 | ERBB INTERFACE PEPTIDOMIMETICS AND METHODS OF USE THEREOF - Peptides, mimetics and antibodies of erbB, TNF, and IgSF receptors and pharmaceutical compositions comprising the same are described. Methods of using such antibodies, peptides, and mimetics in therapeutic, prophylactic, imaging and diagnostic applications are disclosed. | 08-22-2013 |
20140135298 | MUTATION MIMICKING COMPOUNDS THAT BIND TO THE KINASE DOMAIN OF EGFR - This invention is in the fields of cancer therapy. More particularly it concerns compounds which are useful agents for treating cell proliferative disorders, especially those disorders characterized by over activity and/or inappropriate activity of a EGFR, including EGFR-related cancers, particularly for expanding the efficacy of drugs previously developed for this purpose, and for methods of treatments using the compounds for this purpose. | 05-15-2014 |
20140178375 | ANTIBODY-LIKE PROTEINS FOR THERAPEUTIC AND DIAGNOSTIC USE - Disclosed herein are recombinant protein scaffolds for use in producing antigen-binding proteins. Related antigen-binding proteins are also provided herein. In addition, nucleic acids encoding such recombinant protein scaffolds and antigen-binding proteins are also described. Vectors and cells useful for expression of the described proteins are also provided, as are methods of use. | 06-26-2014 |
20140187579 | TIP60 INHIBITORS - This invention is in the fields of immunology and autoimmunity. More particularly it concerns pharmaceutical compositions comprising compounds which are useful agents for inhibiting the functions of TIP60 and the use of such compounds in the treatment of an individual suffering, for example, from ulcerative colitis and other irritable bowel diseases. | 07-03-2014 |
20140234221 | ANTIGEN-BINDING PROTEINS COMPRISING RECOMBINANT PROTEIN SCAFFOLDS - Disclosed herein are recombinant protein scaffolds and recombinant multifunctional protein scaffolds for use in producing antigen-binding proteins In addition, nucleic acids encoding such recombinant protein scaffolds, recombinant multifunctional protein scaffolds, and antigen-binding proteins are provided Vectors and cells useful for expression of the described proteins are also provided, as are methods of use. | 08-21-2014 |
20140256803 | TUMOR NECROSIS FACTOR INHIBITORS - The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions. | 09-11-2014 |
20140309246 | METHODS AND USE OF BIFUNCTIONAL ENZYME-BUILDING CLAMP-SHAPED MOLECULES - This invention is in the fields of cancer therapy. More particularly it concerns compounds which are useful agents for inhibiting cell proliferative disorders, especially those disorders characterized by over activity and/or inappropriate activity of a EGFR, including EGFR-related cancers, and methods for treating these disorders. | 10-16-2014 |
20140348831 | ANTI-PROSTATE CANCER ANTIBODIES AND METHODS OF DETECTION AND TREATMENT OF PROSTATE CANCER USING THE SAME - Disclosed herein are antibodies that detect a lipid-like antigen on prostate cancer cells and methods of detecting and treating prostate cancer using the same. | 11-27-2014 |
20150010551 | Compositions and Methods of Treating Tumors - Methods of treating an individual who has an erbB protein mediated tumor is disclosed. Methods of preventing erbB protein mediated tumors in an individual are disclosed. The methods comprise administering to the individual a nucleic acid molecule that encodes a protein that dimerizes with an erbB protein and that is deficient in tyrosine kinase activity. Composition that comprise such nucleic acid molecules including pharmaceutical compositions are disclosed. | 01-08-2015 |